Biological therapies for inflammatory bowel diseases.

摘要: Crohn's disease and ulcerative colitis are chronic disabling inflammatory bowel diseases (IBDs). Although the causes of IBD unknown, defects in innate adaptive immune pathways have been identified biological therapies that target key molecules designed. Infliximab, a chimeric immunoglobulin (Ig)G1 monoclonal antibody to tumor necrosis factor, dramatically improved treatment patients with colitis. Infliximab has achieved goals such as mucosal healing decreasing need for hospitalizations surgeries. several anti–tumor factor developed, there is great drugs other pathways. Natalizumab, an against integrin α4 subunit, blocks leukocyte adhesion reached clinic United States but not approved European Union; anti-adhesion currently under development. Additional approaches clinical development include therapeutics cytokines, interleukin-12/23, well those block T-cell signaling. The use recombinant human proteins, including immunoregulatory cytokines growth factors, successful so far. efficacy each therapy must be shown carefully designed programs. Biological carry definite safety risk, their place algorithms defined carefully.